Insider Transactions in Q4 2024 at Immunity Bio, Inc. (IBRX)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2024
|
David C. Sachs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,405
-7.12%
|
$30,810
$2.56 P/Share
|
|
Dec 31
2024
|
David C. Sachs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,397
+12.32%
|
-
|
|
Dec 31
2024
|
Richard Adcock CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
17,475
-6.29%
|
$34,950
$2.56 P/Share
|
|
Dec 31
2024
|
Richard Adcock CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
34,483
+11.05%
|
-
|
|
Dec 15
2024
|
Regan J Lauer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,503
-6.5%
|
$15,006
$2.87 P/Share
|
|
Dec 15
2024
|
Regan J Lauer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,031
+15.42%
|
-
|
|
Dec 10
2024
|
Patrick Soon Shiong Director |
BUY
Conversion of derivative security
|
Indirect |
117,185,260
+18.0%
|
$234,370,520
$2.11 P/Share
|